68 results about "Pancreatic A Cells" patented technology

There has been demand for an additional method for producing antibodies. The present invention provides: a polymer-coated crosslinked alginate gel fiber in which a core layer containing a crosslinked alginate gel and either antibody-producing cells (e.g., antibody-producing CHO cells) or bioactive-substance-producing cells (e.g., MIN6 cells derived from pancreatic β cells) is coated with a cationic polymer; and a method for producing antibodies, a bioactive substance, etc., using the fiber.

Disclosed herein are compositions and methods related to differentiation of stem cells into pancreatic endocrine cells. In some aspects, the methods provided herein relate to generation of pancreatic β cell, α cell, δ cells, and EC cells in vitro. In some aspects, the disclosure provides pharmaceutical compositions including the cells generated according to the methods disclosed herein, as well as methods of treatment making use thereof.

Disclosed herein are compositions and methods related to differentiation of stem cells into pancreatic endocrine cells. In some aspects, the methods provided herein relate to generation of pancreatic β cell, α cell, δ cells, and EC cells in vitro. In some aspects, the disclosure provides pharmaceutical compositions including the cells generated according to the methods disclosed herein, as well as methods of treatment making use thereof.

Disclosed herein are compositions and methods related to differentiation of stem cells into pancreatic islet cells. In some aspects, the methods provided herein relate to generation of pancreatic β cell, α cell, δ cells, and EC cells in vitro. In some aspects, the disclosure provides pharmaceutical compositions including the cells generated according to the methods disclosed herein, as well as methods of treatment making use thereof.

Disclosed herein are compositions and methods related to differentiation of stem cells into pancreatic islet cells. In some embodiments, the methods provided herein relate to generation of pancreatic β cell, α cell, δ cells, and EC cells in vitro. In some embodiments, the disclosure provides pharmaceutical compositions including the cells generated according to the methods disclosed herein, as well as methods of treatment making use thereof.

The invention relates to methods of generating pancreatic beta cells using forward reprogramming.

Disclosed herein include methods, compositions, and kits suitable for use in cell therapy. In some embodiments, there are provided methods and compositions for differentiating stem cells into pancreatic beta cells capable of producing insulin.

The present disclosure relates to a method of generating pancreatic lineage cells, e.g. islet-like cell aggregates comprising pancreatic beta cells, comprising the steps of providing a single cell suspension of a population of endocrine progenitor cells (EP), allowing the EP cells in the single cell suspension to form 3D structures, and culturing the cells under conditions allowing differentiation into pancreatic mono-hormonal beta cells. The present disclosure also relates to islet-like cell aggregates obtainable by said method and their medical use.

The present disclosure is based in part on studies on novel tolerogenic peptides derived from a protein expressed by a pancreatic cell, which have been developed for use in antigen-specific immunotherapy for type 1 diabetes. Disclosed is a tolerogenic peptide capable of binding an MHC class II molecule independent of antigen processing for use in the treatment of type 1 diabetes, wherein the peptide is derived from a protein expressed by a pancreatic cell.

The present application discloses cell clusters resembling the function and characteristics of endogenous pancreatic islets, and methods for making and using such cell clusters. The present disclosure provides an in vitro cell cluster comprising at least one non-native pancreatic β cell that exhibits an in vitro glucose-stimulated insulin secretion response when exposed to a glucose challenge, wherein the cell cluster is an unsorted cell cluster, and wherein the cell cluster comprises: at least 35% of cells that express NKX6.1 and C-peptide; at least 70% of cells that express chromogranin A; at most about 2% of cells that express SOX2; or at most about 10% of cells that express SOX9. In some cases, when transplanted into a subject, the in vitro cell cluster exhibits an in vivo glucose-stimulated insulin secretion response to a glucose challenge in the subject.

Provided is a method of differentiating human pluripotent stem cells (hPSCs) into mature pancreatic β cells, comprising contacting hPSC-derived, differentiated immature pancreatic β cells with a histone deacetylase (HDAC) inhibitor.

The present disclosure is based, in part, on the study of novel tolerogenic peptides derived from proteins expressed by pancreatic cells, which peptides have been developed for use for antigen-specific immunotherapy of type 1 diabetes mellitus. Disclosed are tolerogenic peptides capable of binding class II MHC molecules independent of antigen processing for use in the treatment of Type 1 diabetes wherein the peptides are derived from proteins expressed by pancreatic cells.

Disclosed herein are methods of treating a subject for a condition associated with insufficient insulin secretion by administering to a subject in need of treatment for a condition associated with an insufficient level of insulin secretion a dual-specificity tyrosine phosphorylation-regulated kinase 1A (DYRK1A) inhibitor, a glucagon-like peptide-1 receptor (GLP1R) agonist, and an immunomodulatory monoclonal antibody and / or an immunosuppressive agent (e.g., anti-CD3 antibody), where said administering is carried out under conditions effective to reverse loss of β-cell mass and function in the subject to treat the subject for the condition associate with insufficient insulin secretion. Also disclosed is a composition and a method of increasing β-cell mass and function in a population of pancreatic beta cells.

The invention belongs to the technical field of medicines, and particularly relates to preparation of CD317 + MSC cells and application of the CD317 + MSC cells to treatment of type 2 diabetes mellitus. The invention researches the characteristics of CD317 + cells in a heterogeneous UC-MSC population, and finds that the FACS is more beneficial to screening of CD317 + MSCs, and the number of the CD317 + MSCs is gradually increased in in-vitro culture. The expression quantity of stem cell characteristic-related genes in the CD317 + MSC subgroup is obviously increased, which indicates that the stem cell is possibly in an undifferentiated state or affects the differentiation potential, but the effect is transiently and gradually weakened along with culture, which explains that the pluripotent differentiation potential and the like are not obviously changed and are not associated with other potential stem cell surface antigens. The research also finds that the cell is a more favorable subgroup, has unique pluripotency and repair / substitution characteristics, can realize stem cell rejuvenation phenotype, can improve pancreas beta cell functions, reduces diabetic complications, enables partial patients to be independent of insulin, and improves the treatment effect on type 2 diabetes mellitus.

To provide SC-β cells and compositions as well as methods for generating the same.SOLUTION: Disclosed is a composition for use in a method for administering to a human subject with type I diabetes, where the composition comprises a plurality of cell clusters, where the method comprises a step of administering the composition to the subject, where the plurality of cell clusters comprise a plurality of glucagon-expressing cells, all of the cell clusters in the composition have a diameter less than 300 μm, at least 20% of the cells in the plurality of cell clusters are non-native pancreatic β cells that: (a) express chromogranin A, ISL1, PDX1 and C-peptide, and one or more of the following genes ZNT8, MNX1 or ABCC8; and (b) do not express somatostatin or glucagon.SELECTED DRAWING: None

The present disclosure is based in part on research related to novel tolerogenic peptides derived from proteins expressed by pancreatic cells, developed for use in antigen-specific immunotherapy for type 1 diabetes. Disclosed are tolerogenic peptides that can bind to MHC class II molecules without relying on antigen processing, and are derived from proteins expressed by pancreatic cells, for use in the treatment of type 1 diabetes.

Methods and compositions for generating human pancreatic beta cells and progenitor cells thereof from human pluripotent stem cells using chemically defined media are disclosed. The method can preliminarily generate FOXA2 + HNFlb + dorsal anterior intestinal endoderm cells (DFECs), and according to the provided method, the cells can be further differentiated into human PTF1A + PDX1 + pancreatic progenitor cells (PPCs) and human INS + PDX + pancreatic beta cells (PBCs). The invention also provides a culture medium, an isolated cell population and a kit.

A method for inducing differentiation into pancreatic α cells, said method comprising: (a) a step for culturing endodermal cells, which are obtained by induced differentiation from pluripotent stem cells, in the presence of a bone morphogenetic protein (BMP) signal inhibitor and retinoic acid or a retinoic acid analog to thereby induce the differentiation thereof into primitive gut tube (PGT) cells; (b) a step for culturing the PGT cells and thus inducing the differentiation thereof into pancreatic endocrine precursor (EP) cells; and (c) a step for culturing the EP cells and thus inducing the differentiation thereof into pancreatic α cells, wherein the aforesaid steps (b) and (c) are carried out in the absence of ascorbic acid.

The present disclosure provides novel methods for increasing β-cell viability in islets by delivering RLIP76 polypeptides or GSTA4 polypeptides, or a combination thereof; or RLIP76 polynucleotides or GSTA4 polynucleotides, or a combination thereof, to the islets. The disclosure also provides novel methods for treating a disease or condition in a subject, such as type 1 diabetes mellitus, by delivering RLIP76 polypeptides or GSTA4 polypeptides, or a combination thereof; or RLIP76 polynucleotides or GSTA4 polynucleotides, or a combination thereof, to islets and transplanting the islets into the subject to treat the disease or condition. Kits and compositions including RLIP76 polypeptides or GSTA4 polypeptides, or a combination thereof; or RLIP76 polynucleotides or GSTA4 polynucleotides, or a combination thereof, are also provided to increase β-cell viability.

The present invention relates to the field of biomedicine, and discloses a human pancreatic cancer cell line and its application. The pancreatic cancer cell line is a human pancreatic cancer cell line Pahz-1R1 with a biological preservation number of CCTCC NO: C2022354. The tumor formation rate of the cell line is as high as 100%, and it can be used to establish an animal pancreatic cancer model to study biomedical issues such as the mechanism of pancreatic cell carcinogenesis, tumor metastasis, and the preparation of drugs for treating pancreatic cancer; at the same time, the antibodies produced by the cell line can be used to culture 3D organs or organoids, and have broad application value and application prospects.

The present disclosure provides a use of a substance targeting BRD4 in the preparation of a product related to diabetes. In the present disclosure, it is found that the expression of BRD4 in human diabetic beta cells is significantly reduced, and BRD4 plays an important role in maintaining beta cell maturation and differentiation, and long-term and acute BRD4 deficiency can lead to reduced insulin secretion and down-regulation of differentiation markers, highlighting the key role of BRD4 in pancreatic beta cells, providing a target BRD4 that has a significant impact on diabetes, so that substances targeting BRD4 can help to assess the susceptibility of diabetes, screening, prevention, intervention and treatment of diabetes.

Disclosed herein are compositions and methods related to differentiation of stem cells into pancreatic islet cells. In some aspects, the methods provided herein relate to generation of pancreatic β cell, α cell, δ cells, and EC cells in vitro. In some aspects, the disclosure provides pharmaceutical compositions including the cells generated according to the methods disclosed herein, as well as methods of treatment making use thereof.

3D cell cultures and devices for 3D cell culture, and methods of use thereof are provided. In some embodiments, the 3D cell culture comprise pancreatic β cells and can be generated in multi-well plates, allowing for high throughput assays on the cell culture.

The invention discloses a pancreatic beta cell precursor cell transplantation chip based on human-derived iPSC (induced pluripotent stem cell) as well as a preparation method and application of the pancreatic beta cell precursor cell transplantation chip. The chip is composed of beta cell precursor cells (expressing Pdx1, Nkx6.1 and NeuroD1) and a porous degradable bracket (PCL / hyaluronic acid composite material), wherein the beta cell precursor cells (expressing Pdx1, Nkx6.1 and NeuroD1) are obtained by performing four-stage induction on autologous iPSC. The preparation method comprises the steps of autologous iPSC acquisition, beta cell precursor cell induction, three-dimensional bracket preparation and chip assembly. After the chip is implanted into the pancreas of a patient through minimally invasive surgery, precursor cells are differentiated into mature beta cells in vivo, insulin is secreted, the stent is gradually degraded, the pancreas islet function can be fundamentally improved, and the chip is used for treating type I and type II diabetes mellitus. The invention avoids immunological rejection, improves cell survival and functional stability, and has significant clinical transformation value.

Provided herein is a pharmaceutical composition comprising 1-2 part by weight of Schisandra chinensis powder and 5-10 part by weight of extract of Psidium guajava L. The composition can be used in the treatment of reducing blood uric acid, protecting pancreatic beta cell, and reducing body fat.

The present disclosure relates to antibodies or antigen-binding fragments thereof that bind specifically to the glucagon-like peptide 1 receptor (GLP1R) protein, and methods of use thereof. In various embodiments, the antibodies or antigen-binding fragments thereof are fully human antibodies that bind to GLP1R. In some embodiments, the antibodies or antigen-binding fragments thereof are useful for attenuating GLP1R activity, thus providing a means of treating, preventing, or alleviating a disease, disorder or condition associated with GLP1R in humans. In some embodiments, the antibodies or antigen-binding fragments thereof elevate glucose levels when administered to a subject and thereby treat hypoglycemia, such as post-bariatric hypoglycemia (PBH), by attenuating insulin secretion from pancreatic beta cells and decreasing insulin expression.

The present disclosure relates to a device for applying electrical stimulation to biological tissues. Specifically, the present disclosure is related to a device for applying anodal / cathodal biphasic electrical stimulation to beta cells of the pancreas. Through application of biphasic stimulation to beta cells of the pancreas, insulin secretion can be increased in an effort to overcome deficiencies associated with diabetic patients.

The present disclosure relates to a method for generating pancreatic lineage cells, such as pancreatic beta cells, comprising the step of culturing a cell population of post-intestinal cells for no more than about 84 hours under conditions that allow differentiation into pancreatic progenitor cells. The disclosure also relates to pancreatic lineage cells obtainable by said method and medical uses thereof.

The present disclosure generally relates to methods, assays, devices and kits for measuring Pancreatic Alpha Cell Protein, detecting early Type 1 diabetes mellitus (T1D), and treating T1D.